William D. Schwieterman

4.4k total citations · 1 hit paper
10 papers, 3.3k citations indexed

About

William D. Schwieterman is a scholar working on Oncology, Epidemiology and Immunology. According to data from OpenAlex, William D. Schwieterman has authored 10 papers receiving a total of 3.3k indexed citations (citations by other indexed papers that have themselves been cited), including 3 papers in Oncology, 3 papers in Epidemiology and 3 papers in Immunology. Recurrent topics in William D. Schwieterman's work include Biosimilars and Bioanalytical Methods (2 papers), Rheumatoid Arthritis Research and Therapies (2 papers) and Cytokine Signaling Pathways and Interactions (2 papers). William D. Schwieterman is often cited by papers focused on Biosimilars and Bioanalytical Methods (2 papers), Rheumatoid Arthritis Research and Therapies (2 papers) and Cytokine Signaling Pathways and Interactions (2 papers). William D. Schwieterman collaborates with scholars based in United States and Thailand. William D. Schwieterman's co-authors include Jeffrey Siegel, Robert P. Wise, Sharon K. Gershon, M. Miles Braun, Joseph Keane, John Kasznica, S Brown, Evelyne T. Edwards, Jong‐Hoon Lee and Nancy R. Slifman and has published in prestigious journals such as New England Journal of Medicine, Proceedings of the National Academy of Sciences and The Journal of Immunology.

In The Last Decade

William D. Schwieterman

10 papers receiving 3.1k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Tuberculosis Associated with Infliximab, a Tumor Necrosis Factor α–Neutralizing Agent

2001 2.7k citations Joseph Keane, Sharon K. Gershon et al. New England Journal of Medicine profile →

Peers

Countries citing papers authored by William D. Schwieterman

Since Specialization

Citations

This map shows the geographic impact of William D. Schwieterman's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by William D. Schwieterman with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites William D. Schwieterman more than expected).

Fields of papers citing papers by William D. Schwieterman

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by William D. Schwieterman. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by William D. Schwieterman. The network helps show where William D. Schwieterman may publish in the future.

Co-authorship network of co-authors of William D. Schwieterman

This figure shows the co-authorship network connecting the top 25 collaborators of William D. Schwieterman. A scholar is included among the top collaborators of William D. Schwieterman based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with William D. Schwieterman. William D. Schwieterman is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

10 of 10 papers shown

#	Work	Indexed citations
1	Issues in the design of new clinical trials for rheumatoid arthritis therapeutics 2008 ·Nature Clinical Practice Rheumatology ·William D. Schwieterman	8
2	Regulating biopharmaceuticals under CDER versus CBER: an insider's perspective 2006 ·Drug Discovery Today ·William D. Schwieterman	9
3	Life‐threatening histoplasmosis complicating immunotherapy with tumor necrosis factor α antagonists infliximab and etanercept 2002 ·Arthritis & Rheumatism ·Jong‐Hoon Lee, Nancy R. Slifman, Sharon K. Gershon, Evelyne T. Edwards, William D. Schwieterman, Jeffrey Siegel, Robert P. Wise, S Brown, John N. Udall, M. Miles Braun	337
4	Tuberculosis Associated with Infliximab, a Tumor Necrosis Factor α–Neutralizing Agent breakdown → 2001 ·New England Journal of Medicine ·Joseph Keane, Sharon K. Gershon, Robert P. Wise, (unknown), John Kasznica, William D. Schwieterman, Jeffrey Siegel, M. Miles Braun	2706
5	FDA perspective on anti-TNF treatments 1999 ·Annals of the Rheumatic Diseases ·William D. Schwieterman	4
6	Fda Perspective on Study Design for Therapies for Severe Sepsis 1997 ·William D. Schwieterman, Rosemary Roberts	2
7	Studies of Marrow Progenitor Abnormalities in Lupus-Prone Mice 1994 ·Clinical Immunology and Immunopathology ·William D. Schwieterman, (unknown), Dennis M. Klinman, Alfred D. Steinberg	2
8	Studies of bone marrow progenitor cells in lupus-prone mice. I. NZB marrow cells demonstrate increased growth in Whitlock-Witte culture and increased splenic colony-forming unit activity in the Thy-1-, lineage- population 1992 ·The Journal of Immunology ·William D. Schwieterman, G M Wood, D Scott, (unknown)	5
9	Uptake of oleate by isolated rat adipocytes is mediated by a 40-kDa plasma membrane fatty acid binding protein closely related to that in liver and gut. 1988 ·Proceedings of the National Academy of Sciences ·William D. Schwieterman, Dario Sorrentino, Barry J. Potter, Jacob H. Rand, C L Kiang, Decherd Stump, P D Berk	139
10	Isolation and partial characterization of plasma membrane fatty acid binding proteins from myocardium and adipose tissue and their relationship to analogous proteins in liver and gut 1987 ·Biochemical and Biophysical Research Communications ·Barry J. Potter, Decherd Stump, William D. Schwieterman, Dario Sorrentino, (unknown), (unknown), Jacob H. Rand, P D Berk	46

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact